Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Trial Profile

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs FATE NK100 (Primary) ; Interleukin-2
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms APOLLO
  • Most Recent Events

    • 29 Mar 2018 Results (n=2) presented in the Fate Therapeutics Media Release.
    • 29 Mar 2018 According to a Fate Therapeutics media release, results (n=2) are presented at the Innate Killer Summit 2018.
    • 05 Mar 2018 According to a Fate Therapeutics media release, company will present the initial data from this study at the 3rd Innate Killer Summit.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top